Cancer is a scourge on society. One in two Americans will be diagnosed with cancer during their lifetime and one in five will die. The five-year cancer survival rates approach 90% when diagnosed in the earliest stages of the disease versus just 10% in the latest stages.
We believe it doesn’t have to be this way.
Assembled a deep clinical evidence library with data collected from more than 1,200 subjects
More than 20 premier cancer institutions around the world participated in our clinical trials
IONIQ's ProLung Test was awarded “Breakthrough Device Designation” by US FDA for its life-enhancing potential
Robust, growing intellectual portfolio of patents and know-how
IONIQ Sciences Proudly Announces that Mrs. Jan Poulsen is a Lung Cancer Hero Salt Lake City, UT, November 15, 2021 – IONIQ Sciences, Inc. (“IONIQ” or the “Company”), is delighted to share that Mrs. Jan Poulsen, our friend, has been highlighted by CURE® in their Lung
IONIQ Sciences Announces MedTech Breakthrough Award for “Oncology Innovation of the Year 2021” Salt Lake City, UT, November 10, 2021 – IONIQ Sciences, Inc. (“IONIQ” or the “Company”), has been awarded the prestigious “Oncology Innovation of the Year 2021” by MedTech Breakthrough Awards. IONIQ Sciences is
IONIQ Sciences Announces the Appointment of Aaron B. Dorny to its Board of Directors Salt Lake City, UT, October 7, 2021 – IONIQ Sciences, Inc. (“IONIQ” or the “Company”), is developing a rapid and non-invasive Multi-Cancer Screen for early detection that has the potential to
